[HTML][HTML] Sialylation of Prion Protein Controls the Rate of Prion Amplification, the Cross-Species Barrier, the Ratio of PrPSc Glycoform and Prion Infectivity
E Katorcha, N Makarava, R Savtchenko… - PLoS …, 2014 - journals.plos.org
E Katorcha, N Makarava, R Savtchenko, A d′ Azzo, IV Baskakov
PLoS pathogens, 2014•journals.plos.orgThe central event underlying prion diseases involves conformational change of the cellular
form of the prion protein (PrPC) into the disease-associated, transmissible form (PrPSc).
PrPC is a sialoglycoprotein that contains two conserved N-glycosylation sites. Among the
key parameters that control prion replication identified over the years are amino acid
sequence of host PrPC and the strain-specific structure of PrPSc. The current work highlights
the previously unappreciated role of sialylation of PrPC glycans in prion pathogenesis …
form of the prion protein (PrPC) into the disease-associated, transmissible form (PrPSc).
PrPC is a sialoglycoprotein that contains two conserved N-glycosylation sites. Among the
key parameters that control prion replication identified over the years are amino acid
sequence of host PrPC and the strain-specific structure of PrPSc. The current work highlights
the previously unappreciated role of sialylation of PrPC glycans in prion pathogenesis …
The central event underlying prion diseases involves conformational change of the cellular form of the prion protein (PrPC) into the disease-associated, transmissible form (PrPSc). PrPC is a sialoglycoprotein that contains two conserved N-glycosylation sites. Among the key parameters that control prion replication identified over the years are amino acid sequence of host PrPC and the strain-specific structure of PrPSc. The current work highlights the previously unappreciated role of sialylation of PrPC glycans in prion pathogenesis, including its role in controlling prion replication rate, infectivity, cross-species barrier and PrPSc glycoform ratio. The current study demonstrates that undersialylated PrPC is selected during prion amplification in Protein Misfolding Cyclic Amplification (PMCAb) at the expense of oversialylated PrPC. As a result, PMCAb-derived PrPSc was less sialylated than brain-derived PrPSc. A decrease in PrPSc sialylation correlated with a drop in infectivity of PMCAb-derived material. Nevertheless, enzymatic de-sialylation of PrPC using sialidase was found to increase the rate of PrPSc amplification in PMCAb from 10- to 10,000-fold in a strain-dependent manner. Moreover, de-sialylation of PrPC reduced or eliminated a species barrier of for prion amplification in PMCAb. These results suggest that the negative charge of sialic acid controls the energy barrier of homologous and heterologous prion replication. Surprisingly, the sialylation status of PrPC was also found to control PrPSc glycoform ratio. A decrease in PrPC sialylation levels resulted in a higher percentage of the diglycosylated glycoform in PrPSc. 2D analysis of charge distribution revealed that the sialylation status of brain-derived PrPC differed from that of spleen-derived PrPC. Knocking out lysosomal sialidase Neu1 did not change the sialylation status of brain-derived PrPC, suggesting that Neu1 is not responsible for desialylation of PrPC. The current work highlights previously unappreciated role of PrPC sialylation in prion diseases and opens multiple new research directions, including development of new therapeutic approaches.
PLOS